A citation-based method for searching scientific literature

David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
Times Cited: 292

Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel, Coert J Zuurbier. Diabetologia 2018
Times Cited: 177

List of shared articles

Times cited

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021

Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh. Heart 2021

Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci,[...]. Front Med (Lausanne) 2021

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.
Lei Xiao, Xin Nie, Yanyan Cheng, Nanping Wang. Cardiovasc Drugs Ther 2021

The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
Jiang Liu, Jiang Tian, Komal Sodhi, Joseph I Shapiro. J Membr Biol 2021

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes.
Erik J M van Bommel, Mark M Smits, Danique Ruiter, Marcel H A Muskiet, Mark H H Kramer, Max Nieuwdorp, Daan J Touw, Hiddo J L Heerspink, Jaap A Joles, Daniël H van Raalte. J Hypertens 2020

2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu,[...]. J Chin Med Assoc 2020

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019

Metabolism of the failing heart and the impact of SGLT2 inhibitors.
Alvaro Garcia-Ropero, Carlos G Santos-Gallego, M Urooj Zafar, Juan J Badimon. Expert Opin Drug Metab Toxicol 2019